Hospital
Southwest Mississippi Regional Medical Center
Southwest Mississippi Regional Medical Center was paid $46.62M by Medicaid between Jan 2018 and Dec 2024, across 403 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoSOUTHWEST MISSISSIPPI REGIONAL MEDICAL CENTER
MCCOMB, MS 39648
MCCOMB, MS 39648
33aNPI1407805971assigned 05/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$46.62M
24GClaims1,240,009
24DCodes billed403
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#8 of 77
Median peer was paid$8.23M
This provider vs. median5.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROWLEY, CHARLA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 197,354 | $7.91M | |
| 2019 | 181,070 | $7.54M | |
| 2020 | 167,274 | $5.72M | |
| 2021 | 174,720 | $6.52M | |
| 2022 | 184,441 | $7.01M | |
| 2023 | 197,607 | $6.85M | |
| 2024incomplete | 137,543 | $5.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 54,427 | 44,360 | $7.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.2% | 26,598 | 21,269 | $4.29M |
| G0378 | Hospital observation service, per hour | 4.3% | 6,757 | 4,663 | $2.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 9,273 | 7,675 | $2.01M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.2% | 1,448 | 1,235 | $1.51M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 14,231 | 11,123 | $1.31M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.6% | 402 | 334 | $1.20M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 11,933 | 7,949 | $1.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 11,456 | 9,941 | $970K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 6,730 | 5,694 | $938K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 25,243 | 16,943 | $855K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.7% | 2,878 | 2,597 | $793K |
391 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.7% | 5,252 | $781K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 2,419 | $754K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 4,156 | $725K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 16,562 | $672K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 1,400 | $576K |
| D7140 | Extraction, erupted tooth or exposed root | 1.2% | 1,540 | $540K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 7,468 | $534K |
| J0897 | Injection, denosumab, 1 mg | 1.0% | 945 | $488K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 14,240 | $483K |
| D2930 | Prefabricated stainless steel crown - primary tooth | 1.0% | 6,714 | $480K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 17,507 | $479K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,132 | $440K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,666 | $421K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,713 | $419K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,106 | $406K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,100 | $406K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12,240 | $401K |
| 59025 | Fetal non-stress test | <1% | 3,601 | $368K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,770 | $364K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,465 | $350K |
| 80053 | Comprehensive metabolic panel | <1% | 52,591 | $350K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,368 | $334K |
| 86900 | <1% | 5,579 | $322K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 66,176 | $301K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,317 | $294K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,866 | $270K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,846 | $270K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,055 | $238K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 743 | $215K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 599 | $206K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,531 | $203K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 115 | $203K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 587 | $195K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,758 | $189K |
| 76801 | <1% | 2,878 | $188K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 7,739 | $185K |
| 93458 | <1% | 165 | $173K | |
| 96367 | <1% | 3,570 | $157K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 275 | $157K |
| 93017 | <1% | 1,892 | $147K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 339 | $146K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,555 | $144K |
| 93976 | <1% | 2,365 | $142K | |
| 83880 | <1% | 7,685 | $139K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,716 | $137K |
| 43248 | <1% | 581 | $136K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 53,792 | $132K |
| 86850 | <1% | 5,430 | $131K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,838 | $128K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,859 | $123K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,827 | $122K |
| 88312 | <1% | 3,954 | $121K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,217 | $118K |
| 74018 | <1% | 2,809 | $117K | |
| 74019 | <1% | 1,920 | $116K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,507 | $109K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,404 | $109K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,893 | $107K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,054 | $106K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,599 | $106K |
| 84484 | <1% | 16,537 | $105K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 30 | $104K |
| 86901 | <1% | 5,575 | $97K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,235 | $95K |
| 72100 | <1% | 1,738 | $90K | |
| 81025 | <1% | 15,365 | $89K | |
| 73560 | <1% | 2,312 | $87K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 622 | $85K |
| 93226 | <1% | 3,265 | $85K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,006 | $76K |
| 36430 | <1% | 652 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,077 | $76K |
| 81001 | <1% | 37,591 | $74K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 11,206 | $72K |
| 73630 | <1% | 1,790 | $71K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 849 | $69K |
| 82553 | <1% | 11,682 | $67K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,203 | $65K |
| 80061 | Lipid panel | <1% | 7,108 | $65K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,160 | $65K |
| 88313 | <1% | 3,497 | $64K | |
| 43235 | <1% | 224 | $64K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,053 | $64K |
| 93925 | <1% | 877 | $60K | |
| 73610 | <1% | 1,422 | $59K | |
| 86003 | <1% | 513 | $58K | |
| 36600 | <1% | 1,939 | $58K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,034 | $57K |
| 80074 | <1% | 1,709 | $56K | |
| 73030 | <1% | 1,452 | $52K | |
| 82550 | <1% | 12,436 | $51K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 44 | $50K |
| 82805 | <1% | 1,627 | $49K | |
| 52214 | <1% | 34 | $48K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,122 | $47K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 271 | $46K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 782 | $45K |
| 82728 | <1% | 5,359 | $43K | |
| 73130 | <1% | 984 | $42K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 502 | $41K |
| 93971 | <1% | 995 | $40K | |
| 86140 | <1% | 14,499 | $39K | |
| 83615 | <1% | 10,304 | $39K | |
| 88304 | <1% | 1,342 | $38K | |
| 97602 | <1% | 1,030 | $38K | |
| 71250 | <1% | 965 | $37K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 878 | $37K |
| 84702 | <1% | 3,453 | $37K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 444 | $36K |
| 76642 | <1% | 1,072 | $35K | |
| 87807 | <1% | 3,238 | $35K | |
| 83690 | <1% | 8,397 | $35K | |
| J0517 | Injection, benralizumab, 1 mg | <1% | 33 | $34K |
| 87070 | <1% | 5,139 | $34K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 508 | $33K |
| D4355 | <1% | 939 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,204 | $32K |
| 96415 | <1% | 802 | $32K | |
| 87186 | <1% | 5,340 | $32K | |
| 87040 | <1% | 5,864 | $31K | |
| 78264 | <1% | 195 | $31K | |
| 83735 | <1% | 9,138 | $31K | |
| 87150 | <1% | 1,186 | $31K | |
| 95811 | <1% | 90 | $30K | |
| 96417 | <1% | 847 | $30K | |
| 97162 | <1% | 706 | $29K | |
| 82607 | <1% | 3,053 | $29K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,139 | $29K |
| 93922 | <1% | 726 | $28K | |
| D1120 | Dental cleaning, child | <1% | 1,974 | $28K |
| 85027 | <1% | 6,326 | $27K | |
| 73110 | <1% | 617 | $25K | |
| 97161 | <1% | 629 | $25K | |
| 83550 | <1% | 5,222 | $25K | |
| 80081 | <1% | 427 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 345 | $24K |
| 10060 | <1% | 225 | $23K | |
| 94762 | <1% | 464 | $23K | |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | <1% | 24 | $23K |
| 83605 | <1% | 4,458 | $22K | |
| 93970 | <1% | 255 | $21K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 290 | $21K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 121 | $21K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 213 | $19K |
| 87088 | <1% | 3,645 | $19K | |
| 73502 | <1% | 590 | $19K | |
| 82962 | <1% | 10,275 | $19K | |
| 80076 | <1% | 3,547 | $18K | |
| 77066 | Tomosynthesis, mammo | <1% | 292 | $18K |
| 84439 | <1% | 3,457 | $17K | |
| 85379 | <1% | 3,492 | $17K | |
| 77065 | Tomosynthesis, mammo | <1% | 394 | $17K |
| 82746 | <1% | 2,023 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 824 | $16K |
| 86762 | <1% | 1,558 | $16K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 51 | $16K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 306 | $16K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 687 | $15K |
| 82105 | <1% | 1,271 | $15K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 97 | $15K |
| 88300 | <1% | 736 | $15K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 98 | $15K |
| 52224 | <1% | 14 | $14K | |
| 77412 | <1% | 105 | $14K | |
| 83540 | <1% | 3,737 | $14K | |
| 77336 | <1% | 200 | $13K | |
| 85610 | <1% | 5,968 | $13K | |
| 87507 | <1% | 63 | $13K | |
| 82077 | <1% | 1,273 | $13K | |
| 70486 | <1% | 248 | $13K | |
| 84153 | <1% | 1,496 | $12K | |
| 86592 | <1% | 3,906 | $12K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 1,123 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 719 | $12K |
| 72131 | <1% | 311 | $11K | |
| 87077 | <1% | 1,649 | $11K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 509 | $10K |
| 93880 | <1% | 172 | $10K | |
| 72040 | <1% | 325 | $10K | |
| 86300 | <1% | 750 | $9K | |
| 51702 | <1% | 311 | $9K | |
| 83883 | <1% | 703 | $9K | |
| 12001 | <1% | 80 | $9K | |
| 82565 | <1% | 2,014 | $8K | |
| 82677 | <1% | 437 | $8K | |
| 87810 | <1% | 309 | $8K | |
| 86334 | <1% | 789 | $8K | |
| 84165 | <1% | 1,638 | $7K | |
| 85730 | <1% | 2,288 | $7K | |
| 82784 | <1% | 786 | $6K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 72 | $6K |
| 96411 | <1% | 254 | $6K | |
| 76770 | <1% | 109 | $6K | |
| 73562 | <1% | 153 | $6K | |
| D1206 | Topical application of fluoride varnish | <1% | 567 | $6K |
| 73590 | <1% | 182 | $6K | |
| 86803 | <1% | 840 | $6K | |
| 84520 | <1% | 1,981 | $6K | |
| 86038 | <1% | 814 | $6K | |
| 82803 | <1% | 434 | $6K | |
| 86336 | <1% | 437 | $5K | |
| 87340 | <1% | 942 | $5K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 34 | $5K |
| 73140 | <1% | 145 | $5K | |
| 85660 | <1% | 1,174 | $5K | |
| 83520 | <1% | 301 | $5K | |
| 82330 | <1% | 681 | $4K | |
| 73090 | <1% | 114 | $4K | |
| 86780 | <1% | 457 | $4K | |
| 82378 | <1% | 538 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 175 | $4K |
| 73070 | <1% | 112 | $4K | |
| 82947 | <1% | 1,933 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,783 | $4K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 75 | $3K |
| 86923 | <1% | 60 | $3K | |
| 85651 | <1% | 1,255 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,533 | $3K |
| 87081 | <1% | 581 | $3K | |
| 84703 | <1% | 533 | $3K | |
| 87427 | <1% | 534 | $3K | |
| 82785 | <1% | 236 | $3K | |
| A6266 | Gauze, impregnated, other than water, normal saline, or zinc paste, sterile, any width, per linear yard | <1% | 2,434 | $2K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 52 | $2K |
| 82150 | <1% | 506 | $2K | |
| 82010 | <1% | 461 | $2K | |
| 87045 | <1% | 282 | $2K | |
| 87046 | <1% | 271 | $2K | |
| 84550 | <1% | 638 | $2K | |
| 96523 | <1% | 103 | $2K | |
| 86704 | <1% | 371 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 152 | $2K |
| 76775 | <1% | 52 | $2K | |
| 85045 | <1% | 958 | $2K | |
| 73552 | <1% | 49 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20,128 | $2K |
| 84132 | <1% | 1,195 | $2K | |
| 81003 | <1% | 1,026 | $2K | |
| 85007 | <1% | 984 | $2K | |
| D2330 | <1% | 46 | $2K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 376 | $2K |
| 72072 | <1% | 29 | $2K | |
| 70498 | <1% | 38 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 430 | $2K |
| 0240U | <1% | 596 | $1K | |
| A9270 | Non-covered item or service | <1% | 10,992 | $1K |
| 82375 | <1% | 315 | $1K | |
| D1351 | Sealant - per tooth | <1% | 95 | $1K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 205 | $1K |
| 82247 | <1% | 255 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,990 | $1K |
| 80069 | <1% | 473 | $1K | |
| 87205 | <1% | 436 | $1K | |
| 82435 | <1% | 661 | $1K | |
| 12011 | <1% | 22 | $942.26 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,156 | $931.87 |
| 97165 | <1% | 21 | $922.27 | |
| 84295 | <1% | 686 | $918.38 | |
| 83050 | <1% | 315 | $883.27 | |
| 97163 | <1% | 13 | $801.33 | |
| 93242 | <1% | 66 | $795.83 | |
| 80143 | <1% | 62 | $788.66 | |
| 87210 | <1% | 227 | $767.66 | |
| 82570 | <1% | 330 | $754.33 | |
| 51701 | <1% | 16 | $746.50 | |
| 97014 | <1% | 69 | $733.96 | |
| 70496 | <1% | 13 | $731.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,747 | $681.19 |
| A6253 | Specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing | <1% | 892 | $652.88 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 221 | $641.85 |
| 85014 | <1% | 442 | $628.28 | |
| 80179 | <1% | 44 | $553.74 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,704 | $551.15 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 4,320 | $500.28 |
| 82533 | <1% | 150 | $483.81 | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 14 | $477.35 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,909 | $471.85 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,827 | $443.12 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,785 | $441.00 |
| 85018 | <1% | 542 | $441.00 | |
| 84100 | <1% | 295 | $432.61 | |
| 90756 | <1% | 40 | $398.48 | |
| 82043 | <1% | 139 | $390.41 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,420 | $376.92 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,340 | $374.13 |
| 0077U | <1% | 938 | $353.83 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $321.92 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,942 | $317.84 |
| 82950 | <1% | 94 | $317.13 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,297 | $302.95 |
| A6251 | Specialty absorptive dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 571 | $290.40 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,004 | $258.80 |
| 83521 | <1% | 1,085 | $250.15 | |
| 90686 | <1% | 19 | $236.72 | |
| C1769 | Guide wire | <1% | 2,298 | $227.33 |
| 91200 | <1% | 27 | $215.26 | |
| 82977 | <1% | 42 | $210.71 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,435 | $201.48 |
| 84145 | <1% | 3,837 | $194.91 | |
| 84156 | <1% | 82 | $186.10 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,516 | $167.25 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 3,643 | $145.86 |
| J3490 | Unclassified drugs | <1% | 537 | $138.74 |
| 96376 | <1% | 6,948 | $124.11 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,868 | $98.19 |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 119 | $96.80 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,380 | $94.07 |
| J1815 | Injection, insulin, per 5 units | <1% | 3,182 | $91.99 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,117 | $88.86 |
| 99152 | <1% | 1,342 | $87.79 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 726 | $81.77 |
| 88302 | <1% | 22 | $79.24 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 156 | $78.18 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,955 | $70.94 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,984 | $69.39 |
| 84155 | <1% | 67 | $66.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 449 | $60.28 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 492 | $54.41 |
| 94664 | <1% | 5,699 | $47.20 | |
| 86308 | <1% | 13 | $46.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 997 | $43.25 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 226 | $42.50 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 215 | $41.56 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 948 | $41.05 |
| 94760 | <1% | 2,240 | $39.17 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 503 | $37.93 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,181 | $36.60 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,016 | $36.21 |
| 0296T | <1% | 12 | $35.78 | |
| 77061 | <1% | 15 | $32.90 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 354 | $30.38 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,188 | $28.56 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 746 | $25.68 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 329 | $20.95 |
| A6260 | Wound cleansers, any type, any size | <1% | 43 | $19.36 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 688 | $18.41 |
| 90715 | <1% | 885 | $18.38 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,487 | $12.16 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 392 | $9.77 |
| 77062 | <1% | 28 | $8.58 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 506 | $7.47 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 228 | $5.64 |
| J2704 | Injection, propofol, 10 mg | <1% | 306 | $5.47 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 15 | $4.30 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 140 | $3.35 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 882 | $2.79 |
| A6445 | Conforming bandage, non-elastic, knitted/woven, sterile, width less than three inches, per yard | <1% | 1,641 | $2.65 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,024 | $1.67 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 106 | $0.55 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 374 | $0.16 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 200 | $0.00 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 372 | $0.00 |
| A6203 | Composite dressing, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 612 | $0.00 |
| L8613 | Ossicula implant | 0% | 1,196 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 4,106 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 1,542 | $0.00 |
| 0427U | 0% | 809 | $0.00 | |
| A4332 | Lubricant, individual sterile packet, each | 0% | 327 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 464 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 198 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 15 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 380 | $0.00 |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 75 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 16 | $0.00 |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml | 0% | 106 | $0.00 |
| 77012 | 0% | 13 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 24 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 77 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 30 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 27 | $0.00 |
| 93356 | 0% | 25 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 24 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 39 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| 36000 | 0% | 286 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 28 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 116 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 328 | $0.00 |
| 81511 | 0% | 16 | $0.00 | |
| 96377 | 0% | 46 | $0.00 | |
| 80050 | General health panel | 0% | 66 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 239 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 13 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 71 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 17 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 36 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 95 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 97 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 114 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROWLEY, CHARLA (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.